Kelly Knupp, MD

The pediatric epileptologist at Children's Hospital Colorado talked about a comprehensive review of various studies assessing fenfluramine in severe seizures associated with developmental and epileptic encephalopathies. [WATCH TIME: 5 minutes]

Mary Anne Meskis; Tracy Dixon-Salazar, PhD; Kelly Knupp, MD; and Joseph E. Sullivan, MD, provide advice for physicians treating patients with Dravet syndrome or LGS.

Kelly Knupp, MD; Mary Anne Meskis; and Tracy Dixon-Salazar, PhD, share education around patient advocacy and support groups as well as other resources for patients with Dravet syndrome or LGS.

Tracy Dixon-Salazar, PhD, leads a discussion on challenges of treating LGS and real-world implications from clinical trial data on newer medications.

Kelly Knupp, MD, provides insight on optimizing treatment for patients with Lennox-Gastaut Syndrome.

Dr Kelly Knupp examines data on fenfluramine and cannabidiol for the management of Lennox-Gastaut Syndrome.

Joseph E. Sullivan, MD, leads a discussion on treatment options for the management of patients with LGS and considers the impact of treatment on quality of life.

Kelly Knupp, MD, shares her perspective of a provider journey of a new patient with LGS and goal setting to manage the disease.

Tracy Dixon-Salazar, PhD, reflects on her daughter’s journey to diagnosis of Lennox-Gastaut Syndrome and the impact of the disease on caregivers.

Tracy Dixon-Salazar, PhD, and Kelly Knupp, MD, emphasize key identifiers for the diagnosis of Lennox-Gastaut Syndrome and challenges in managing seizures in these patients.

Kelly Knupp, MD, provides an overview of Lennox-Gastaut Syndrome (LGS).

Joseph E. Sullivan, MD, and Kelly Knupp, MD, share strategies for managing patients who have suboptimal seizure control with medications.

Joseph E. Sullivan, MD, and Kelly Knupp, MD, evaluate the use of stiripentol in clinical practice for the management of Dravet syndrome and Mary Anne Meskis discusses the honeymoon effect of drugs.

Expert pediatric neurologists assess the use of fenfluramine and comment on its impact on seizure freedom for patients with Dravet syndrome.

Kelly Knupp, MD, reviews available treatment options indicated for Dravet syndrome and shares her thoughts on the use of cannabidiol for patients.

Kelly Knupp, MD, leads a discussion on goals of treatment for patients who are earlier in their treatment journey.

Dr Kelly Knupp, Dr Joseph E. Sullivan, and Mary Anne Meskis comment on the impact of Dravet syndrome on a patient and their caregiver’s quality of life and address education around SUDEP.

Kelly Knupp, MD, reviews the patient presentation of Dravet syndrome and the recognition of common signs and symptoms in patients.

Kelly Knupp, MD; Joseph E. Sullivan, MD; and Mary Anne Meskis review diagnosis of Dravet syndrome and the role of genetic testing.

Kelly Knupp, MD, provides an overview of Dravet syndrome and shares insight on discerning the diagnosis of disease from febrile seizures.

The pediatric neurologist and epilepsy specialist at Colorado Children’s Hospital discussed new data presented at AAN 2022 on the use of recently approved fenfluramine in patients with Lennox-Gastaut syndrome. [WATCH TIME: 3 minutes]

The pediatric neurologist and epilepsy specialist at Colorado Children’s Hospital discussed how the treatment landscape for patients with Lennox-Gastaut syndrome could alter if fenfluramine is approved.

The pediatric neurologist and epilepsy specialist at Children’s Hospital Colorado detailed the results of study of fenfluramine in patients with Lennox-Gastaut syndrome.

The pediatric neurologist and epilepsy specialist at Children’s Hospital Colorado discussed the popularity of cannabidiol from coverage in the media, and how she sees its use—and the understanding of it—evolving in the coming years.

The pediatric neurologist and epilepsy specialist at Children’s Hospital Colorado spoke about the need to continue to research therapies once they’re approved to better understand their use, and how cannabidiol falls into this category.